Literature DB >> 33361040

The role of the Epstein-Barr virus-encoded BARF1 gene expressed in human gastric epithelial cells.

Shuying Li1, Fang Zhang1, Ji Li1, Xuya Hu1, Wei Zhao1, Ke Zhang1, Jintao Li2.   

Abstract

BACKGROUND/AIMS: The study aimed to explore the effects of Epstein-Barr virus--encoded BARF1 in human gastric epithelial cells (GES-1).
MATERIALS AND METHODS: A eukaryotic expression vector carrying BARF1 gene (pcDNA3.1-BARF1) was constructed. The pcDNA3.1-BARF1 was transfected into GES-1 cells, and they were selected by G418. The GES-1 cells lines that expressed BARF1 (GES-1-BARF1) were obtained. The cycle of GES-1-pcDNA3.1 cells (GES-1 cells transfected with empty vector), GES-1-BARF1 cells (GES-1 cells transfected with BARF1), and TPA-GES-1-BARF1(GES-1-BARF1 cells stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA) were analyzed by flow cytometry. Colony formation in soft agar and tumorigenicity of the transfected cells in mice with severe combined immunodeficiency (SCID) were also observed.
RESULTS: The morphology of GES-1-BARF1 cells were changed from the original shuttle to round, the adhesion between the cells and bottle wall was weakened, and the cells showed overlapping growth. The proliferation rate of GES-1-BARF1 and TPA-GES-1-BARF1 cells were faster than GES-1 and GES-1-pcDNA3.1 cells; the S phase was significantly prolonged for GES-1-BARF1 and TPA-GES-1-BARF1. GES-1-BARF1 and TPA-GES-1-BARF1 cells formed colonies in soft agar, with a cloning rate of 24.2% (58/240) and 40.0% (96/240), respectively; GES-1 and GES-1-pcDNA3.1 cells did not form colonies in soft agar. Tumors were formed in mice with SCID after injecting TPA-GES-1-BARF1 cell groups. Tumor formation did not occur in mice with SCID after injecting GES-1 and GES-1-pcDNA3.1 cell groups, but nodules were formed in the mice with SCID after injecting GES-1-BARF1 cell groups.
CONCLUSION: GES-1-BARF1 cells malignant transformation was induced by transfected BARF1 gene and TPA stimulation. This result indicated that tumor formation not only require oncogenes, but also the stimulation of cancer-promoting substance.

Entities:  

Year:  2020        PMID: 33361040      PMCID: PMC7759223          DOI: 10.5152/tjg.2020.18827

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  30 in total

1.  Unique variations of Epstein-Barr virus-encoded BARF1 gene in nasopharyngeal carcinoma biopsies.

Authors:  Yun Wang; Xiao-Feng Wang; Zhi-Fu Sun; Bing Luo
Journal:  Virus Res       Date:  2012-03-01       Impact factor: 3.303

2.  Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein.

Authors:  Alhousseynou Sall; Sophie Caserta; Pierre Jolicoeur; Laure Franqueville; Mireille de Turenne-Tessier; Tadamasa Ooka
Journal:  Oncogene       Date:  2004-06-17       Impact factor: 9.867

3.  The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor.

Authors:  L D Strockbine; J I Cohen; T Farrah; S D Lyman; F Wagener; R F DuBose; R J Armitage; M K Spriggs
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression.

Authors:  Eri Seto; Lixin Yang; Jaap Middeldorp; Tzung-Shiahn Sheen; Jen-Yan Chen; Masashi Fukayama; Yoshito Eizuru; Tadamasa Ooka; Kenzo Takada
Journal:  J Med Virol       Date:  2005-05       Impact factor: 2.327

5.  Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-κB.

Authors:  Mee Soo Chang; Dong Ha Kim; Jin Kyung Roh; Jaap M Middeldorp; Yang Soo Kim; Sunghan Kim; Seungbong Han; Chul Woo Kim; Byung Lan Lee; Woo Ho Kim; Jun Hee Woo
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

6.  Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy.

Authors:  Debora Martorelli; Karim Houali; Laura Caggiari; Emanuela Vaccher; Luigi Barzan; Giovanni Franchin; Annunziata Gloghini; Alessandro Pavan; Alessandro Da Ponte; Rosa Maria Tedeschi; Valli De Re; Antonino Carbone; Tadamasa Ooka; Paolo De Paoli; Riccardo Dolcetti
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

7.  Recent Advances on the Possible Neuroprotective Activities of Epstein-Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System.

Authors:  Alicia Wynne; Rupinder K Kanwar; Rajiv Khanna; Jagat R Kanwar
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

8.  Expression of BamHI-A Rightward Transcripts in Epstein-Barr Virus-Associated Gastric Cancers.

Authors:  Bo-Gun Jang; Eun Ji Jung; Woo Ho Kim
Journal:  Cancer Res Treat       Date:  2011-12-27       Impact factor: 4.679

Review 9.  Epstein-Barr Virus: Diseases Linked to Infection and Transformation.

Authors:  Hem C Jha; Yonggang Pei; Erle S Robertson
Journal:  Front Microbiol       Date:  2016-10-25       Impact factor: 5.640

Review 10.  Epstein-Barr Virus (EBV)-associated gastric carcinoma.

Authors:  Hisashi Iizasa; Asuka Nanbo; Jun Nishikawa; Masahisa Jinushi; Hironori Yoshiyama
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more
  1 in total

1.  Acrid-release and bitter-downbearing therapy and banxia xiexin decoction regulate Wnt/β-catenin pathway, inhibit proliferation and invasion, and induce apoptosis in gastric cancer cells.

Authors:  Xiaofen Sun; Dewen Xue; Kanru Zhang; Fang Jiang; Duoqiao Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.